Abstract
The 2-year efficacy and safety of once-weekly (OW) subcutaneous semaglutide 2.4 mg versus placebo in adults with overweight/obesity was assessed in STEP 5 (NCT03693430). In STEP 5 (phase 3, double-blind, placebo-controlled trial), adults with body mass index (BMI) ≥30 kg/m2, or ≥27 kg/m2 with ≥1 weight-related comorbidity, without diabetes, were randomized 1:1 to 104 weeks’ treatment with OW semaglutide 2.4 mg or placebo. Co-primary endpoints were percent change in body weight (BW) and achievement of ≥5% weight loss.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
